Published online 2 June 2008
Haematologica, Vol 93, Issue 9, 1376-1379 doi:10.3324/haematol.12896
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Woodburn, K. W.
Right arrow Articles by Norton, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woodburn, K. W.
Right arrow Articles by Norton, D.

Erythropoiesis

Chronic preclinical safety evaluation of HematideTM, a pegylated peptidic erythropoiesis stimulating agent in monkeys

Kathryn W. Woodburn1, Susan D. Wilson2, Kei-lai Fong3, Peter J. Schatz1, Thomas Ferrell4, Charles B. Spainhour4, Daniel Norton4

1 Affymax, Inc., Palo Alto, CA
2 Aclairo Pharmaceutical Development Group, Inc, Vienna, VA
3 Pennsylvania Biolab Inc., Radnor, PA
4 Calvert Laboratories, Olyphant, PA, USA

Correspondence: Kathryn W. Woodburn, PhD, Affymax, Inc, 4001 Miranda Avenue, Palo Alto, CA, 94304 USA. E-mail:kathryn_woodburn{at}affymax.com

Hematide is a synthetic peptide-based, pegylated erythropoiesis stimulating agent in clinical development for treatment of anemia. To support chronic clinical dosing requirements, a 9-month repeat dose IV monkey safety study was undertaken. Animals received 0, 0.2, 2 or 20 mg/kg hematide IV every three weeks for nine months followed by a 14-week recovery. Hematide administration was associated with time and dose-dependent polycythemia. Histological findings were related to exaggerated pharmacology that was secondary to the administration of an erythropoiesis stimulating agent to a normocythemic animal. In conclusion, these results support the use of repeated administration of hematide for the correction of anemia.

Key words: erythropoiesis, hematopoiesis, pharmacology, safety, pharmacokinetics.